Brown adipose tissue demonstrating intense FDG uptake in a patient with mediastinal pheochromocytoma

Annals of Nuclear Medicine

Volumn 22, Issue 3, 2008, Pages 231-235

  Kuji, Ichiei ^a   Imabayashi, Etsuko ^a   Minagawa, Akinobu ^b   Matsuda, Hiroshi ^a   Miyauchi, Tsutomu ^c  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c Toyama Medical Health Center   (Japan)

Author keywords

Brown adipose tissue; Extra adrenal pheochromocytoma; F 18 fluorodeoxyglucose; Positron emission tomography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CATECHOLAMINE; FLUORODEOXYGLUCOSE F 18; PENTETIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BROWN ADIPOSE TISSUE; CASE REPORT; CATECHOLAMINE BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FEMALE; HEART LEFT ATRIUM; HUMAN; HUMAN TISSUE; HYPERTENSION; MEDIASTINUM TUMOR; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL;

3-IODOBENZYLGUANIDINE; ABDOMINAL NEOPLASMS; ADIPOSE TISSUE, BROWN; ADRENAL GLAND NEOPLASMS; ADULT; BONE NEOPLASMS; CATECHOLAMINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; HYPERTENSION; LYMPHATIC METASTASIS; MEDIASTINAL NEOPLASMS; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44349084943     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0096-x     Document Type: Article

References (17)

1. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology 1993;186:711-715.
2. Maurea S, Mainolfi C, Wang H, Varrella P, Panico MR, Klain M, et al. Positron emission tomography (PET) with F-18-fluorodeoxyglucose in the study of adrenal masses: comparison of benign and malignant lesions. Radiol Med (Torino) 1996;92:782-787.
3. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 2002;29:1393-1398.
4. 18F-FDG PET/CT. J Nucl Med 2003;44:170-176.
5. Fukuchi K, Tatsumi M, Ishida Y, Oku N, Hatazawa J, Wahl RL. Radionuclide imaging metabolic activity of brown adipose tissue in a patient with pheochromocytoma. Exp Clin Endocrinol Diabetes 2004;112:601-603.
6. English JT, Patel SK, Flanagan MJ. Association of pheochromocytomas with brown fat tumors. Radiology 1973;107:279-281.
7. Lean ME, James WP, Jennings G, Trayhurn P. Brown adipose tissue in patients with phaeochromocytoma. Int J Obes 1986;10:219-227.
8. Elsayes KM, Narra VR, Leyendecker JR, Francis IR, Lewis JS Jr, Brown JJ. MRI of adrenal and extraadrenal pheochromocytoma. AJR Am J Roentgenol 2005;184:860-867.
9. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997;46:39-44.
10. Chernogubova E, Cannon B, Bengtsson T. Norepinephrine increases glucose transport in brown adipocytes via beta 3-adrenoceptors through a cAMP, PKA, and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinology 2004;145:269-280.
11. 18F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 2004;45:1189-1193.
12. Soderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propranolol. Eur J Nucl Med Mol Imaging 2007;34:1018-1022.
13. Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Dobert N, et al. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca 2003;30:37-40.
14. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin Nucl Med 2005;30:579-581.
15. Glodny B, Winde G, Herwig R, Meier A, Kuhle C, Cromme S, et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J 2001;48:151-159.
16. Kumaki N, Kajiwara H, Kameyama K, DeLellis RA, Asa SL, Osamura RY, et al. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques. Endocr Pathol 2002;13:149-156.
17. Elsayes KM, Mukundan G, Narra VR, Lewis JS Jr, Shirkhoda A, Farooki A, et al. Adrenal masses: MR imaging features with pathologic correlation. Radiographics 2004;24Suppl 1:S73-S86.